Quantbot Technologies LP Invests $2.28 Million in Humana Inc (HUM) Stock

Quantbot Technologies LP acquired a new position in Humana Inc (NYSE:HUM) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 6,749 shares of the insurance provider’s stock, valued at approximately $2,284,000.

A number of other institutional investors have also modified their holdings of the business. Financial Gravity Wealth Inc. raised its stake in Humana by 41.9% in the 3rd quarter. Financial Gravity Wealth Inc. now owns 562 shares of the insurance provider’s stock worth $179,000 after purchasing an additional 166 shares in the last quarter. Carillon Tower Advisers Inc. increased its holdings in Humana by 0.6% in the 3rd quarter. Carillon Tower Advisers Inc. now owns 27,160 shares of the insurance provider’s stock valued at $9,194,000 after buying an additional 168 shares during the period. San Francisco Sentry Investment Group CA increased its holdings in Humana by 46.9% in the 3rd quarter. San Francisco Sentry Investment Group CA now owns 598 shares of the insurance provider’s stock valued at $203,000 after buying an additional 191 shares during the period. Oppenheimer Asset Management Inc. increased its holdings in Humana by 1.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,901 shares of the insurance provider’s stock valued at $3,541,000 after buying an additional 197 shares during the period. Finally, CIBC World Markets Inc. increased its holdings in Humana by 0.7% in the 3rd quarter. CIBC World Markets Inc. now owns 30,069 shares of the insurance provider’s stock valued at $10,179,000 after buying an additional 198 shares during the period. Institutional investors and hedge funds own 93.05% of the company’s stock.

Shares of Humana stock opened at $330.29 on Friday. The company has a market cap of $45.12 billion, a P/E ratio of 28.21, a P/E/G ratio of 1.56 and a beta of 1.03. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.68 and a current ratio of 1.68. Humana Inc has a 1 year low of $242.00 and a 1 year high of $355.88.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.29 by $0.29. The company had revenue of $14.21 billion for the quarter, compared to analyst estimates of $13.97 billion. Humana had a net margin of 2.70% and a return on equity of 19.10%. During the same period in the previous year, the firm posted $3.39 EPS. Equities research analysts forecast that Humana Inc will post 14.43 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 25th. Investors of record on Monday, December 31st will be given a dividend of $0.50 per share. The ex-dividend date is Friday, December 28th. This represents a $2.00 annualized dividend and a yield of 0.61%. Humana’s dividend payout ratio is presently 11.96%.

In related news, insider Roy A. Beveridge sold 4,622 shares of Humana stock in a transaction that occurred on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total transaction of $1,576,379.32. Following the sale, the insider now directly owns 10,621 shares in the company, valued at approximately $3,622,398.26. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bruce D. Broussard sold 18,000 shares of Humana stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the sale, the chief executive officer now owns 71,085 shares in the company, valued at $23,362,796.10. The disclosure for this sale can be found here. 0.60% of the stock is owned by company insiders.

Several equities analysts have commented on HUM shares. Argus raised their target price on shares of Humana to $375.00 and gave the company a “buy” rating in a report on Tuesday, September 4th. Piper Jaffray Companies reissued a “buy” rating and issued a $355.00 target price on shares of Humana in a report on Thursday, August 2nd. Bank of America raised their target price on shares of Humana from $338.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, August 2nd. Jefferies Financial Group raised their target price on shares of Humana from $356.00 to $372.00 and gave the company a “buy” rating in a report on Thursday, August 2nd. Finally, Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $377.00 target price on the stock in a report on Thursday, October 4th. Seven research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Humana currently has a consensus rating of “Buy” and a consensus target price of $352.30.

TRADEMARK VIOLATION NOTICE: This article was first reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://www.americanbankingnews.com/2018/11/30/quantbot-technologies-lp-invests-2-28-million-in-humana-inc-hum-stock.html.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

See Also: Preferred Stock

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply